HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

Electronic Letters to:

reviews: Jonathan P. Parsons and John G. Mastronarde Exercise-Induced Bronchoconstriction in Athletes Chest 2005; 128: 3966-3974 [Abstract] [Full text] [PDF]

eLetters: Submit a response to this article

Electronic letters published:

Attention to doping controls required when prescribing for athletes.

Andrew McD Johnston   (16 December 2005)

Attention to doping controls required when prescribing for athletes. 16 December 2005
Andrew McD Johnston, Specialist Registrar in Respiratory and Intensive Care Medicine University of Birmingham and Defence Medical Services, United Kingdom Send letter to journal: Re: Attention to doping controls required when prescribing for athletes. amcdj{at}doctors.org.uk Andrew McD Johnston	To the Editor, In their review of exercise induced bronchoconstriction in athletes Parsons and Mastronarde correctly advocate the use of beta-2 agonists and inhaled corticosteroids.[1] Physicians who treat competitive athletes should be aware, however, that athletes competing at national and international level require a “Therapeutic Use Exemption” for these classes of drug. This is a certificate obtainable from the athlete’s national sports federation or national anti doping agency, which allows their physician to inform the governing body that the athlete requires this treatment. The athlete may then be granted approval to use the drug, and avoid censure if it is unexpectedly found during anti- doping tests.[2] 1. Parsons JP, Mastronarde JG. Exercise-Induced Bronchoconstriction in Athletes. Chest. 2005;128:3966-3974. 2. World anti-Doping Agency. International Standard for Therapeutic Use Exemptions; available at http://www.wada-ama.org/en/dynamic.ch2? pageCategory.id=373 Accessed December 15, 2005